Eppendorf Expands Single-Use Vessel Portfolio
PTSM: Pharmaceutical Technology Sourcing and Management
The company announced that it will be expanding its portfolio of single-use vessels for fermentation.
On July 5, 2016, Eppendorf announced that it would be expanding its portfolio of rigid-wall single-use vessels for fermentation. According to the company, the Eppendorf BioBLU 3f was developed specifically for microbial bioprocessing in working volumes of 1.25 to 3.75 L, extending the full range of operation for single-use fermentation from 60 mL to 3.75 L.
Eppendorf BioBLU f Single-Use Vessels specifically address the demands of high cell density fermentation of bacteria, yeasts, and fungi. Magnetic overhead drives featuring impellers support agitation rates up to 1200 rpm and provide high-performance mass transfer. The integrated cooling baffles enable efficient heat removal for exothermic processes and the rigid-wall industrial stirred-tank design ensures scalability and simplifies technology transfer.
Source: Eppendorf
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
